The U.S. Food and Drug Administration (FDA) has approved nerandomilast, an oral medication developed by Boehringer Ingelheim, to treat adults with idiopathic pulmonary fibrosis (IPF) — when the lung disease has no known cause. The therapy will be marketed under the brand name Jascayd. According to a…
FDA approves Jascayd as first new IPF treatment in over 10 years
In just over a month, one of the largest gatherings of pulmonary fibrosis (PF) patients, caregivers, and health professionals will take place in Chicago, at the Pulmonary Fibrosis Foundation (PFF) Summit 2025. My idiopathic pulmonary fibrosis (IPF) diagnosis in January 2017 thrust my wife, Susan, and me…
Treatment with the experimental therapy nerandomilast appears to reduce the risk of death in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), according to a new analysis of clinical trial data presented by the therapy’s developer, Boehringer Ingelheim. “The new pooled data zoom in on…
My journey to a diagnosis of idiopathic pulmonary fibrosis (IPF) began in the fall of 2016, when I was 59. It all started with a persistent cough. While the cough was annoying, especially to my wife, Susan, it wasn’t limiting my day-to-day activities. After seeing a radiologist’s report, my…
In 2009, I was at a point in my career in cardiology where I’d helped save many lives. I could spell both “pulmonary” and “fibrosis” because of some early transcription work I’d done, but I didn’t know much about pulmonary fibrosis (PF). I was quickly introduced to it when my…
LTI-03, an experimental treatment for idiopathic pulmonary fibrosis (IPF) that’s currently in clinical testing, was shown to reduce inflammation and scarring in experiments done on lung tissue collected from IPF patients, according to a study. The study showed that LTI-03’s effects on inflammation and scarring were similar to those…
From the day I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, I set out to learn everything I could about the disease. This included how to tell others about IPF, which is so named because its cause isn’t known. When a transplant isn’t a viable…
GRI-0621, an experimental oral therapy for idiopathic pulmonary fibrosis (IPF), may stabilize lung function, according to an interim analysis of an ongoing Phase 2a study. Forced vital capacity (FVC), a measure of how much air a person can forcibly exhale, didn’t worsen during the first six weeks of the…
I’m at it again; I’m job hunting, or seeking employment, if you will. But this time, the search carries more weight. It’s not just about finding work; it’s about reclaiming a part of myself that I thought I’d lost. Teaching has always been my passion, the steady flame that keeps…
There will be times when, despite everything you cover in planning for a trip, something happens that you didn’t anticipate. I can guarantee it. I shared with you my vacation details and preparations in my Aug. 26 column, all made to ensure the entire trip would be an opportunity…
Your PF Community
Recent Posts
- Gut bacteria B. adolescentis may be new preventive treatment for PF January 7, 2026
- On my diagnosis journey, I felt like I was moving in slow motion January 6, 2026
- Amid a sea of data, the PF community is critical in the search for a cure December 23, 2025
- FDA approves Jascayd for adults with progressive pulmonary fibrosis December 23, 2025
- Oral therapy GRI-0621 boosts lung function, repairs tissue in IPF: Data December 17, 2025
